Small molecule activators of protein phosphatase 2A for the treatment of endometrial cancer

cell lines, using the most potent and clinically relevant synergistic drug combinations identified by the screen. Results: Drug library screening revealed synergistic activity between B and specific classes of drugs, including taxanes, histone deacetylase (HDAC) inhibitors, and polo-like kinase (PLK) inhibitors. We proceeded to confirm results with docetaxel, panobinostat, volasertib, and olaparib in vitro. Favorable activity was observed using B with docetaxel, panobinostat, and volasertib but not with olaparib in eight ovarian cancer cell lines. Conclusions: An unbiased matrix screening platform enabled rapid identification of rational therapeutic combinations for the treatment of ovarian cancer. We identified three possible combinations to increase the anticancer activity of B. Future studies will evaluate the preclinical and clinical impact of these combinations.